Apheresis Market

Report Code MD 1407
Published in Apr, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Apheresis Market Size by Product (Device (Centrifugation, Membrane Separation) Disposable), Procedure (Donor, Therapeutic), Application (Plasmapheresis, Plateletpheresis), Technology, End-User (Hospital, Blood Collection Center), Region - Global Forecast to 2029

Overview

The global apheresis market in terms of revenue was estimated to be worth USD 2.6 billion in 2024 and is poised to reach USD 3.9 billion by 2029, growing at a CAGR of 8.8% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth of the market is mainly driven by upsurge in demand for source plasma from biopharmaceutical companies, and increase in demand for blood components and growing concerns regarding blood safety.

Attractive Opportunities in the Apheresis Market

North America

Factors such as the increase in prevalence of chronic diseases, such as cardiovascular diseases, cancer, and autoimmune disorders & rising instances of surgical procedures are driving the adoption of apheresis market in this region

The growth of this market can be attributed to the increasing incidences of trauma and injury cases, rising demand for plasma, and blood components and growing concerns regarding blood safety, and increase in number of complex surgical procedures, and favorable reimbursement for apheresis procedures.

North America dominates the apheresis market. This apheresis market is projected to reach USD 1.7 billion by 2029, at a CAGR of 8.4% during the forecast period.

Emerging economies with increasing investments from government bodies and key players are expected to offer growth opportunities for market players during the forecast period.

The APAC market is projected to register the highest growth in the forecast period owing to the large population and rising healthcare needs

Global Apheresis Market Dynamics

DRIVER: Rise in number of chronic diseases across the globe

The upsurging prevalence of chronic diseases worldwide serves as a key driving factor in the expansion of the market. Chronic conditions are characterized by their prolonged duration and gradual progression, encompass a wide range of diseases such as cardiovascular diseases, diabetes, cancer, and autoimmune disorders. For instance, according to the Evidence-Based Practice of Palliative Medicine Second Edition released in 2023, nearly half of individuals aged 65 to 69 suffer from two or more chronic ailments, a figure that rises to 75% among those over 85. Thus, as the populations age and lifestyle patterns evolve, the incidence of chronic diseases continues to climb, generating heightened demand for advanced therapeutic solutions like apheresis. Apheresis procedures offer a precise method for managing diseases by removing harmful substances from the bloodstream. Moreover, with ongoing technological innovations and increasing awareness among healthcare professionals and patients, apheresis procedures are becoming more accessible and are being progressively incorporated into treatment methods for effectively managing chronic diseases. thus, increasing the growth of the market throughout the forecast period.

RESTRAINT: High cost of apheresis devices decreasing the adoption

The market faces a significant restraining factor in the form of the high cost associated with apheresis devices, which in turn impedes their widespread adoption. The substantial initial investment required to acquire apheresis devices presents a barrier to their adoption, particularly for smaller healthcare facilities or those operating in resource-constrained settings. Moreoer, the high cost of apheresis devices encompasses not only the purchase price but also maintenance, consumables, and specialized training for healthcare professionals. This financial burden may dissuade healthcare providers from investing in apheresis technology, limiting patient access to these potentially life-saving procedures. Additionally, concerns regarding the cost-effectiveness of apheresis treatments compared to alternative therapies or traditional blood banking methods may further impact adoption rates.

 

OPPORTUNITY: Apheresis for leukemia and pediatric patients

The growing adoption of mainly therapeutic apheresis, particularly in the treatment of diseases such as leukemia, presents a significant opportunity within the market, particularly for paediatric patients. For instance, in the US for 2024, the American Cancer Society projects approximately 62,770 new instances of leukemia across all subtypes, with an estimated 23,670 fatalities attributed to the disease. The apheresis process involves removing specific components from a patient's blood and returning the rest to the body. In the case of leukemia, therapeutic apheresis plays a crucial role in managing the disease by removing excess white blood cells, which are often malignant, from the patient's bloodstream. This process helps alleviate symptoms and can even contribute to remission in some cases, making it a vital component of leukemia treatment protocols. Additionally, apheresis allows for precise control over the removal of harmful cells, minimizing the risk of complications and reducing the need for aggressive interventions. This makes it a preferred option for many parents and healthcare providers seeking the best possible outcomes for paediatric leukemia patients, thus showing the lucrative growth of the market.

CHALLENGE: Safety of blood transfusion in developing countries

The safety of blood transfusions in developing countries poses a significant challenge for the market, primarily due to concerns surrounding the transmission of infectious agents such as HIV, HBV, and others. In many developing regions, blood transfusion services face various obstacles, including inadequate infrastructure, limited resources, and insufficient regulatory oversight. As a result, there is a heightened risk of transfusion-transmitted infections, which can have severe consequences for both patients and healthcare systems. Moreover, increasing prevalence of infectious diseases underscore the importance of addressing transfusion safety on a global scale. The emergence of new pathogens and the potential for outbreaks pose ongoing challenges for blood transfusion services, particularly in regions with limited capacity for screening and testing. Thus, the safety concerns of blood transfusion in developing countries is posing a challenge to the market.

Global Apheresis Market Ecosystem Analysis

ECOSYSTEM ANALYSIS/MARKET MAP Prominent companies in this market are market Terumo BCT, Inc. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Baxter International Inc. (US), Asahi Kasei Medical Co., Ltd. (Japan), B. Braun Melsungen AG (Germany), Cerus Corporation (US), Kaneka Corporation (Japan), SB-Kawasumi Laboratories, Inc (Japan), ), LMB Technologie GmbH (Germany), Bioelettronica S.r.l. (Italy), Infomed SA (Switzerland), Cytosorbents Corporation (US), Nikkiso Co., Ltd (Japan), Macopharma SA (France), Miltenyi Biotec (Germany), Otsuka Holdings Co., Ltd. (Japan), Medica S.p.A. (Italy), Mallinckrodt plc (Ireland), Becton, Dickinson and Company (US), Medicap clinic GmbH (Germany), Haier Biomedical (China), Beijing ZKSK Technology Co., Ltd. (China), Guangzhou Daji Medical Science and Technology Co. Ltd (China), PuriBlood Medical (Taiwan).

The Device segment is expected to grow at the highest CAGR from 2024 to 2029 in apheresis industry

Based on product, the apheresis market is segmented into apheresis devices and disposables. Among these the apheresis device segment is expected to show the growth of at the fastest rate. The apheresis device segment is again divided into two Sub-segments, centrifugation apheresis device and membrane separators. The centrifugation apheresis device holds the largest share in the apheresis device segment in 2023, attributing to several key advantages it offers over membrane separation technology. As centrifugation apheresis devices are known for their high efficiency in separating blood components, making them a preferred choice for therapeutic procedures hence, these are highly sought after by healthcare providers seeking comprehensive treatment options for various conditions, such as leukaemia, autoimmune disorders, and neurological diseases. This is leading to increasing adoption of centrifugation apheresis devices in hospitals, driving the growth of this segment within the market.

The plasmapheresis accounted for the largest share of the apheresis industry.

By application, the apheresis market is segmented into plasmapheresis, plateletpheresis, erythrocytapheresis, leukapheresis, photopheresis, and other applications including, lipidpheresis, lymphapheresis, immunoadsorption and stem cell collection. Among these, plasmapheresis segment accounted for the largest market share, attributing to its widespread adoption in the treatment of various neurological, immunological, and renal diseases. Plasmapheresis, also known as therapeutic plasma exchange, is a crucial therapeutic intervention utilized in the management of conditions such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), myasthenia gravis, thrombotic thrombocytopenic purpura (TTP), renal diseases, and rheumatic diseases. Its efficacy in removing harmful antibodies, immune complexes, and other pathogenic factors from the plasma makes it an indispensable treatment option for patients suffering from these debilitating illnesses. Thus, as the prevalence of neurological and autoimmune diseases continues to rise globally, the demand for plasmapheresis as a therapeutic intervention is expected to grow substantially, driving the expansion of this market segment.

North America Region Holds the Largest Share of the Apheresis Market.

Based on the region, the apheresis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America accounted for the largest share of the market. This is due to increase in prevalence of chronic diseases, such as cardiovascular diseases, cancer, and autoimmune disorders. This is leading to increased need for therapeutic interventions, including apheresis procedures, to manage these diseases effectively. As a result, healthcare facilities across North America increasingly rely on apheresis technologies to provide crucial treatment options for patients with chronic illnesses, thereby driving the market's growth. Moreover, rising instances of surgical procedures in North America further bolster the demand for apheresis products and services. As surgical interventions often require blood transfusions, necessitating the availability of adequate blood components like platelets and plasma. Apheresis plays a pivotal role in obtaining these specific blood components efficiently and safely, ensuring a steady supply for surgical procedures, thus contributing significantly to the dominance of North America in the market.

 

Key Market Players

KEY PLAYERS IN THE Apheresis Market INCLUDE

  • Terumo BCT, Inc. (Japan)
  • Fresenius SE & Co. KGaA (Germany)
  • Haemonetics Corporation (US)
  •  Baxter International Inc. (US)
  • Asahi Kasei Medical Co., Ltd. (Japan)
  • Medica S.p.A. (Italy)
  • Mallinckrodt plc (Ireland)
  • Becton, Dickinson and Company (US)
  • LMB Technologie GmbH (Germany)
  • Beijing ZKSK Technology Co., Ltd. (China)
  • Guangzhou Daji Medical Science and Technology Co. Ltd (China)
  • Bioelettronica S.r.l. (Italy)
  • Infomed SA (Switzerland)
  • Cytosorbents Corporation (US)
  • Medicap clinic GmbH (Germany)
  • Haier Biomedical (China)
  • B. Braun Melsungen AG (Germany)
  • Cerus Corporation (US)
  • Kaneka Corporation (Japan)
  • SB-Kawasumi Laboratories, Inc (Japan)
  • Nikkiso Co., Ltd (Japan)
  • Macopharma SA (France)
  • Miltenyi Biotec (Germany)
  • Otsuka Holdings Co., Ltd. (Japan)
  • PuriBlood Medical (Taiwan)

Want to explore hidden markets that can drive new revenue in Apheresis Market?

Scope of the Report

Report Attribute Details
Market Revenue in 2024 $2.6 billion
Projected Revenue by 2029 $3.9 billion
Revenue Rate Poised to Grow at a CAGR of 8.8%
Market Driver Rise in number of chronic diseases across the globe
Market Opportunity Apheresis for leukemia and pediatric patients

 

Key Questions Addressed by the Report

What is the projected market revenue value of the global apheresis market?
The global apheresis market boasts a total revenue value of $3.9 billion by 2029.
What is the estimated growth rate (CAGR) of the global apheresis market?
The global apheresis market has an estimated compound annual growth rate (CAGR) of 8.8% and a revenue size in the region of $2.6 billion in 2024.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Apheresis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
29
RESEARCH METHODOLOGY
37
EXECUTIVE SUMMARY
51
PREMIUM INSIGHTS
58
MARKET OVERVIEW
62
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rising prevalence of chronic diseases and trauma/injury cases
    - Increasing demand for source plasma from biopharmaceutical companies
    - Rising demand for blood components and growing concerns regarding blood safety
    - Increase in complex surgical procedures
    - Favorable reimbursement policies for apheresis procedures
    RESTRAINTS
    - High cost of procedures and installation through rental models
    - Limited use in blood donation due to low awareness
    - Stringent donor recruitment criteria
    - Dearth of skilled professionals and low adoption of therapeutic apheresis
    OPPORTUNITIES
    - Apheresis for leukemia and pediatric patients
    - Emerging economies with increasing investments from government bodies and leading players
    CHALLENGES
    - Recruitment of voluntary non-remunerated donors
    - Safety of blood transfusion in developing countries
  • 5.3 INDUSTRY TRENDS
    INCREASE IN FOCUS ON PERSONALIZED MEDICINE
    INCREASE IN FOCUS ON AUTOMATION AND EFFICIENCY
    EXPANSION OF APHERESIS APPLICATIONS
  • 5.4 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Centrifugation
    - Membrane Filtration
    - Automated collection systems
    COMPLEMENTARY TECHNOLOGY
    - Biocompatible Materials
    - Automation and robotics
    - Advanced imaging technologies
    ADJACENT TECHNOLOGIES
    - Extracorporeal Photopheresis (ECP)
    - Continuous Renal Replacement Therapy (CRRT)
    - Hemodialysis
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 REGULATORY LANDSCAPE
    REGULATORY ANALYSIS
    - North America
    - Europe
    - Asia Pacific
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR APHERESIS MARKET
    INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.9 HS CODES: APHERESIS INSTRUMENTS
  • 5.10 PRICING ANALYSIS
  • 5.11 REIMBURSEMENT ANALYSIS
  • 5.12 KEY CONFERENCES AND EVENTS, 2024–2025
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.14 UNMET NEEDS IN APHERESIS MARKET
  • 5.15 END USER EXPECTATIONS IN APHERESIS MARKET
  • 5.16 AI INTEGRATION IN APHERESIS MARKET
  • 5.17 ECOSYSTEM ANALYSIS
  • 5.18 CASE STUDIES
    CASE STUDY 1: ESTIMATING MARKET SIZE OF LEUKAPHERESIS PRODUCTS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL
    CASE STUDY 2: ESTIMATING MARKET SIZE OF LEUKOPAKS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL
    CASE STUDY 3: THERAPEUTIC PLASMA EXCHANGE FOR MYASTHENIA GRAVIS
    CASE STUDY 4: THERAPEUTIC APHERESIS FOR TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI)
  • 5.19 SUPPLY CHAIN ANALYSIS
  • 5.20 ADJACENT MARKET ANALYSIS
    LEUKAPHERESIS MARKET
  • 5.21 APHERESIS MARKET: INVESTMENT AND FUNDING SCENARIO
APHERESIS MARKET, BY PRODUCT
104
  • 6.1 INTRODUCTION
  • 6.2 APHERESIS DISPOSABLES
    RECURRENT USE OF APHERESIS DISPOSABLES TO BOOST GROWTH
  • 6.3 APHERESIS DEVICES
    CENTRIFUGAL APHERESIS DEVICES
    - Increasing installation in hospitals for therapeutic apheresis
    MEMBRANE SEPARATORS
    - Separation of huge volumes of plasma from milliliters of whole blood – key limiting factor
APHERESIS MARKET, BY PROCEDURE
113
  • 7.1 INTRODUCTION
  • 7.2 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS)
    INCREASING NUMBER OF BLOOD COMPONENT DONATIONS USING APHERESIS DEVICES TO SUPPORT MARKET GROWTH
  • 7.3 THERAPEUTIC APHERESIS
    THERAPEUTIC APHERESIS DISPOSABLES
    - Neurological disorders
    - Blood disorders
    - Renal disorders
    - Autoimmune disorders
    - Metabolic disorders
    - Cardiovascular disorders
    - Other disorders
    THERAPEUTIC APHERESIS DEVICES
    - Centrifugation-based devices – most commonly adopted
APHERESIS MARKET, BY TECHNOLOGY
129
  • 8.1 INTRODUCTION
  • 8.2 CENTRIFUGATION
    CONTINUOUS FLOW CENTRIFUGATION
    - Preferred in blood collection and therapeutic apheresis procedures
    INTERMITTENT FLOW CENTRIFUGATION
    - Need for single venipuncture site – major driving factor
  • 8.3 MEMBRANE SEPARATION
    HIGH EFFICACY ACCOUNTS FOR HIGH USAGE IN DEVELOPED COUNTRIES
APHERESIS MARKET, BY APPLICATION
137
  • 9.1 INTRODUCTION
  • 9.2 PLASMAPHERESIS
    LARGEST APPLICATION SEGMENT IN APHERESIS MARKET
  • 9.3 PLATELETPHERESIS
    INCREASING DEMAND FOR PLATELETS IN TRANSFUSIONS TO DRIVE GROWTH
  • 9.4 ERYTHROCYTAPHERESIS
    INCREASING DEMAND FOR RED BLOOD CELLS FOR TRANSFUSION IN SURGICAL PROCEDURES TO DRIVE GROWTH
  • 9.5 LEUKAPHERESIS
    INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE SEGMENT
  • 9.6 PHOTOPHERESIS
    INCREASING PREVALENCE OF BLOOD DISORDERS AND ORGAN TRANSPLANT REJECTION TO DRIVE SEGMENT
  • 9.7 OTHER APPLICATIONS
APHERESIS MARKET, BY END USER
147
  • 10.1 INTRODUCTION
  • 10.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS
    INCREASING AWARENESS OF BENEFITS OF APHERESIS TO FUEL SEGMENT
  • 10.3 HOSPITALS & TRANSFUSION CENTERS
    RISING NUMBER OF COMPLEX SURGICAL PROCEDURES AND TRANSFUSIONS TO BOOST MARKET
  • 10.4 OTHER END USERS
APHERESIS MARKET, BY REGION
152
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    NORTH AMERICA: RECESSION IMPACT
    US
    - Dominates North American apheresis market
    CANADA
    - Rising demand for plasma protein products to drive market growth
  • 11.3 EUROPE
    EUROPE: RECESSION IMPACT
    GERMANY
    - Fastest-growing market for apheresis systems in Europe
    FRANCE
    - Increasing need for blood components to boost market
    ITALY
    - Therapeutic plasma exchange and LDL apheresis - widely adopted procedures
    UK
    - Growing consumption of plasma-derived products to fuel market growth
    SPAIN
    - Growing demand for treatment of chronic diseases in the elderly
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    ASIA PACIFIC: RECESSION IMPACT
    CHINA
    - Dominant Asia Pacific apheresis market
    JAPAN
    - Advanced technology and universal healthcare insurance – key drivers
    INDIA
    - Increasing demand for blood components and growing applications of plasma derivatives – key drivers
    AUSTRALIA
    - Growing awareness campaigns to drive market growth
    SOUTH KOREA
    - Rise in prevalence of blood cancers to drive market growth
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    LATIN AMERICA: RECESSION IMPACT
    BRAZIL
    - Accounts for largest share of Latin American market
    MEXICO
    - Rapidly growing geriatric population – key factor driving market growth
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    MIDDLE EAST & AFRICA: RECESSION IMPACT
    GCC COUNTRIES
    - Increase in prevalence of chronic diseases to drive market
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
248
  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES
  • 12.3 REVENUE SHARE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS
    APHERESIS MARKET SHARE ANALYSIS
    CENTRIFUGATION: APHERESIS MARKET SHARE ANALYSIS
    MEMBRANE SEPARATION: APHERESIS MARKET SHARE ANALYSIS
  • 12.5 COMPANY EVALUATION MATRIX, KEY PLAYERS (2023)
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Region footprint
    - Product footprint
    - Procedure footprint
    - Technology footprint
    - Application footprint
    - End user footprint
  • 12.6 COMPANY EVALUATION MATRIX, START-UP/SMES (2023)
    PROGRESSIVE COMPANIES
    DYNAMIC COMPANIES
    RESPONSIVE COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023
  • 12.7 COMPETITIVE SCENARIO AND TRENDS
    PRODUCT LAUNCHES & APPROVALS
    DEALS
    OTHERS
  • 12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
COMPANY PROFILES
269
  • 13.1 KEY PLAYERS
    TERUMO BCT, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    FRESENIUS SE &CO. KGAA
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    HAEMONETICS CORPORATION
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    BAXTER INTERNATIONAL INC.
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    ASAHI KASEI MEDICAL CO., LTD. (SUBSIDIARY OF ASAHI KASEI CORPORATION)
    - Business overview
    - Products & services offers
    - MnM view
    B. BRAUN MELSUNGEN AG
    - Business overview
    - Products & services offered
    - Recent developments
    CERUS CORPORATION
    - Business overview
    - Products & services offered
    - Recent developments
    KANEKA CORPORATION
    - Business overview
    - Products & services offered
    - Recent developments
    SB-KAWASUMI LABORATORIES, INC. (SUBSIDIARY OF SUMITOMO BAKELITE CO., LTD.)
    - Business overview
    - Products & services offered
    NIKKISO CO., LTD.
    - Business overview
    - Products & services offered
    MACOPHARMA SA
    - Business overview
    - Products & services offered
    MILTENYI BIOTEC
    - Business overview
    - Products & services offered
    OTSUKA HOLDINGS CO., LTD.
    - Business overview
    - Products & services offered
    MEDICA S.P.A.
    - Business overview
    - Products & services offered
    MALLINCKRODT PLC
    - Business overview
    - Products & services offered
    - Recent developments
    BECTON, DICKINSON AND COMPANY
    - Business overview
    - Products & services offered
    LMB TECHNOLOGIE GMBH
    - Business overview
    - Products & services offered
    BIOELETTRONICA S.R.L.
    - Business overview
    - Products & services offered
    INFOMED SA
    - Business overview
    - Products & services offered
    CYTOSORBENTS CORPORATION
    - Business overview
    - Products & services offered
  • 13.2 OTHER PLAYERS
    MEDICAP CLINIC GMBH
    HAIER BIOMEDICAL
    BEIJING ZKSK TECHNOLOGY CO., LTD.
    GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD
    PURIBLOOD MEDICAL
APPENDIX
321
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 CURRENCY CONVERSION RATES
  • TABLE 2 REQUIRED UNITS OF BLOOD AND BLOOD COMPONENTS, BY TYPE OF SURGERY
  • TABLE 3 ESTIMATED BLOOD DONATIONS, BY REGION
  • TABLE 4 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS
  • TABLE 5 APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 LIST OF PATENTS IN APHERESIS MARKET, 2014–2024
  • TABLE 12 HS CODES FOR APHERESIS INSTRUMENTS
  • TABLE 13 PRICING OF APHERESIS PRODUCTS, 2023 (USD)
  • TABLE 14 PRICING ANALYSIS OF APHERESIS PRODUCTS (USD)
  • TABLE 15 REGIONAL PRICING ANALYSIS OF KEY APHERESIS PRODUCTS, 2023 (USD)
  • TABLE 16 REIMBURSEMENT ANALYSIS: FOR APHERESIS PROCEDURES
  • TABLE 17 APHERESIS MARKET: KEY CONFERENCES AND EVENTS, 2024–2025
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR APHERESIS PRODUCTS
  • TABLE 19 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS
  • TABLE 20 UNMET NEEDS: APHERESIS MARKET
  • TABLE 21 END USER EXPECTATIONS: APHERESIS MARKET
  • TABLE 22 AI INTEGRATION: APHERESIS MARKET
  • TABLE 23 ECOSYSTEM OF APHERESIS MARKET
  • TABLE 24 APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 25 APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 26 KEY PLAYERS PROVIDING APHERESIS DISPOSABLES
  • TABLE 27 APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 28 APHERESIS DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 29 CENTRIFUGAL APHERESIS DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 30 KEY PLAYERS PROVIDING CENTRIFUGAL APHERESIS DEVICES
  • TABLE 31 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 32 KEY PLAYERS PROVIDING MEMBRANE SEPARATORS
  • TABLE 33 APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 34 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS), BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 35 THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 36 THERAPEUTIC APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 37 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 38 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 39 NEUROLOGICAL DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 40 BLOOD DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 41 RENAL DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 42 AUTOIMMUNE DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 43 METABOLIC DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 44 CARDIOVASCULAR DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 45 OTHER DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 46 THERAPEUTIC APHERESIS DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 47 APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 48 CONTINUOUS FLOW CENTRIFUGATION VS. INTERMITTENT FLOW CENTRIFUGATION
  • TABLE 49 KEY PLAYERS PROVIDING CENTRIFUGATION TECHNOLOGY
  • TABLE 50 CENTRIFUGATION: APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 51 CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 52 CONTINUOUS FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 53 INTERMITTENT FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 54 SIZE OF BLOOD COMPONENTS
  • TABLE 55 KEY PLAYERS PROVIDING MEMBRANE SEPARATION TECHNOLOGY
  • TABLE 56 MEMBRANE SEPARATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 57 APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 58 PLASMAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 59 PLATELETPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 60 ERYTHROCYTAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 61 LEUKAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 62 PHOTOPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 63 OTHER APPLICATIONS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 64 APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 65 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 66 HOSPITALS & TRANSFUSION CENTERS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 67 OTHER END USERS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 68 APHERESIS MARKET, BY REGION, 2021–2029 (USD MILLION)
  • TABLE 69 NORTH AMERICA: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 70 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 71 NORTH AMERICA: DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 72 NORTH AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 73 NORTH AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 74 NORTH AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 75 NORTH AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 76 NORTH AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 77 NORTH AMERICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 78 NORTH AMERICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 79 US: KEY MACROINDICATORS
  • TABLE 80 US: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 81 US: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 82 US: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 83 US: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 84 US: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 85 US: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 86 US: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 87 US: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 88 US: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 89 CANADA: KEY MACROINDICATORS
  • TABLE 90 CANADA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 91 CANADA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 92 CANADA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 93 CANADA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 94 CANADA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 95 CANADA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 96 CANADA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 97 CANADA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 98 CANADA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 99 EUROPE: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 100 EUROPE: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 101 EUROPE: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 102 EUROPE: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 103 EUROPE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 104 EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 105 EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 106 EUROPE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 107 EUROPE: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 108 EUROPE: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 109 GERMANY: KEY MACROINDICATORS
  • TABLE 110 GERMANY: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 111 GERMANY: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 112 GERMANY: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 113 GERMANY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 114 GERMANY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 115 GERMANY: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 116 GERMANY: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 117 GERMANY: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 118 GERMANY: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 119 FRANCE: KEY MACROINDICATORS
  • TABLE 120 FRANCE: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 121 FRANCE: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 122 FRANCE: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 123 FRANCE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 124 FRANCE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 125 FRANCE: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 126 FRANCE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 127 FRANCE: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 128 FRANCE: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 129 ITALY: KEY MACROINDICATORS
  • TABLE 130 ITALY: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 131 ITALY: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 132 ITALY: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 133 ITALY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 134 ITALY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 135 ITALY: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 136 ITALY: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 137 ITALY: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 138 ITALY: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 139 UK: KEY MACROINDICATORS
  • TABLE 140 UK: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 141 UK: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 142 UK: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 143 UK: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2021–2029 (USD MILLION)
  • TABLE 144 UK: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 145 UK: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 146 UK: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 147 UK: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 148 UK: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 149 SPAIN: KEY MACROINDICATORS
  • TABLE 150 SPAIN: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 151 SPAIN: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 152 SPAIN: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 153 SPAIN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 154 SPAIN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 155 SPAIN: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 156 SPAIN: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 157 SPAIN: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 158 SPAIN: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 159 REST OF EUROPE: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 160 REST OF EUROPE: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 161 REST OF EUROPE: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 162 REST OF EUROPE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 163 REST OF EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 164 REST OF EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 165 REST OF EUROPE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 166 REST OF EUROPE: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 167 REST OF EUROPE: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 168 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 169 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 170 ASIA PACIFIC: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 171 ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 172 ASIA PACIFIC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 173 ASIA PACIFIC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 174 ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 176 ASIA PACIFIC: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 178 CHINA: KEY MACROINDICATORS
  • TABLE 179 CHINA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 180 CHINA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 181 CHINA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 182 CHINA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 183 CHINA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 184 CHINA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 185 CHINA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 186 CHINA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 187 CHINA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 188 JAPAN: KEY MACROINDICATORS
  • TABLE 189 JAPAN: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 190 JAPAN: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 191 JAPAN: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 192 JAPAN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 193 JAPAN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 194 JAPAN: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 195 JAPAN: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 196 JAPAN: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 197 JAPAN: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 198 INDIA: KEY MACROINDICATORS
  • TABLE 199 INDIA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 200 INDIA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 201 INDIA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 202 INDIA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 203 INDIA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 204 INDIA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 205 INDIA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 206 INDIA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 207 INDIA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 208 AUSTRALIA: KEY MACROINDICATORS
  • TABLE 209 AUSTRALIA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 210 AUSTRALIA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 211 AUSTRALIA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 212 AUSTRALIA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 213 AUSTRALIA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 214 AUSTRALIA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 215 AUSTRALIA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 216 AUSTRALIA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 217 AUSTRALIA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 218 SOUTH KOREA: KEY MACROINDICATORS
  • TABLE 219 SOUTH KOREA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 220 SOUTH KOREA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 221 SOUTH KOREA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 222 SOUTH KOREA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 223 SOUTH KOREA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 224 SOUTH KOREA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 225 SOUTH KOREA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 226 SOUTH KOREA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 227 SOUTH KOREA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 228 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 229 REST OF ASIA PACIFIC: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 230 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 231 REST OF ASIA PACIFIC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 232 REST OF ASIA PACIFIC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 233 REST OF ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 234 REST OF ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 235 REST OF ASIA PACIFIC: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 236 REST OF ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 237 LATIN AMERICA: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 238 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 239 LATIN AMERICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 240 LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 241 LATIN AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 242 LATIN AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 243 LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 244 LATIN AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 245 LATIN AMERICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 246 LATIN AMERICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 247 BRAZIL: KEY MACROINDICATORS
  • TABLE 248 BRAZIL: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 249 BRAZIL: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 250 BRAZIL: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 251 BRAZIL: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 252 BRAZIL: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 253 BRAZIL: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 254 BRAZIL: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 255 BRAZIL: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 256 BRAZIL: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 257 MEXICO: KEY MACROINDICATORS
  • TABLE 258 MEXICO: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 259 MEXICO: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 260 MEXICO: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 261 MEXICO: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 262 MEXICO: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 263 MEXICO: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 264 MEXICO: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 265 MEXICO: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 266 MEXICO: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 267 REST OF LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 268 REST OF LATIN AMERICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 269 REST OF LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 270 REST OF LATIN AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 271 REST OF LATIN AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 272 REST OF LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 273 REST OF LATIN AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 274 REST OF LATIN AMERICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 275 REST OF LATIN AMERICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 276 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 277 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 278 MIDDLE EAST & AFRICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 279 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 280 MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 281 MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 282 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 283 MIDDLE EAST & AFRICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 284 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 285 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 286 GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 287 GCC COUNTRIES: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 288 GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 289 GCC COUNTRIES: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 290 GCC COUNTRIES: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 291 GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 292 GCC COUNTRIES: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 293 GCC COUNTRIES: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 294 GCC COUNTRIES: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 295 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 296 REST OF MIDDLE EAST & AFRICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 297 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
  • TABLE 298 REST OF MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 299 REST OF MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 300 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
  • TABLE 301 REST OF MIDDLE EAST & AFRICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 302 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 303 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 304 APHERESIS MARKET: DEGREE OF COMPETITION
  • TABLE 305 CENTRIFUGATION MARKET: DEGREE OF COMPETITION
  • TABLE 306 MEMBRANE SEPARATION MARKET: DEGREE OF COMPETITION
  • TABLE 307 APHERESIS MARKET: REGION FOOTPRINT
  • TABLE 308 APHERESIS MARKET: PRODUCT FOOTPRINT
  • TABLE 309 APHERESIS MARKET: PROCEDURE FOOTPRINT
  • TABLE 310 APHERESIS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 311 APHERESIS MARKET: APPLICATION FOOTPRINT
  • TABLE 312 APHERESIS MARKET: END USER FOOTPRINT
  • TABLE 313 APHERESIS MARKET: KEY START-UPS/SMES
  • TABLE 314 APHERESIS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020–FEBRUARY 2024
  • TABLE 315 APHERESIS MARKET: DEALS, JANUARY 2020–FEBRUARY 2024
  • TABLE 316 APHERESIS MARKET: OTHERS, JANUARY 2020–FEBRUARY 2024
  • TABLE 317 APHERESIS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • TABLE 318 TERUMO BCT, INC.: BUSINESS OVERVIEW
  • TABLE 319 TERUMO BCT, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 320 TERUMO BCT, INC.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 321 TERUMO BCT, INC.: DEALS
  • TABLE 322 TERUMO BCT, INC.: EXPANSIONS
  • TABLE 323 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
  • TABLE 324 FRESENIUS SE &CO. KGAA: PRODUCTS & SERVICES OFFERED
  • TABLE 325 FRESENIUS SE &CO. KGAA: PRODUCT LAUNCHES & APPROVALS
  • TABLE 326 FRESENIUS SE &CO. KGAA: DEALS
  • TABLE 327 FRESENIUS SE &CO. KGAA: EXPANSIONS
  • TABLE 328 HAEMONETICS CORPORATION: BUSINESS OVERVIEW
  • TABLE 329 HAEMONETICS CORPORATION: PRODUCTS & SERVICES OFFERED
  • TABLE 330 HAEMONETICS CORPORATION: PRODUCT LAUNCHES & APPROVALS
  • TABLE 331 HAEMONETICS CORPORATION: DEALS
  • TABLE 332 HAEMONETICS CORPORATION: EXPANSIONS
  • TABLE 333 BAXTER INTERNATIONAL INC.: BUSINESS OVERVIEW
  • TABLE 334 BAXTER INTERNATIONAL INC: PRODUCTS & SERVICES OFFERED
  • TABLE 335 BAXTER INTERNATIONAL INC: OTHERS
  • TABLE 336 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
  • TABLE 337 ASAHI KASEI CORPORATION: PRODUCTS & SERVICES OFFERED
  • TABLE 338 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
  • TABLE 339 B. BRAUN MELSUNGEN AG: PRODUCTS & SERVICES OFFERED
  • TABLE 340 B. BRAUN MELSUNGEN AG: DEALS
  • TABLE 341 B. BRAUN MELSUNGEN AG: OTHERS
  • TABLE 342 CERUS CORPORATION: BUSINESS OVERVIEW
  • TABLE 343 CERUS CORPORATION: PRODUCTS & SERVICES OFFERED
  • TABLE 344 CERUS CORPORATION: PRODUCT LAUNCHES & APPROVALS
  • TABLE 345 CERUS CORPORATION: DEALS
  • TABLE 346 CERUS CORPORATION: OTHERS
  • TABLE 347 KANEKA CORPORATION: BUSINESS OVERVIEW
  • TABLE 348 KANEKA CORPORATION: PRODUCTS & SERVICES OFFERED
  • TABLE 349 KANEKA CORPORATION: DEALS
  • TABLE 350 KANEKA CORPORATION: OTHERS
  • TABLE 351 SB-KAWASUMI LABORATORIES: BUSINESS OVERVIEW
  • TABLE 352 SB-KAWASUMI LABORATORIES: PRODUCTS & SERVICES OFFERED
  • TABLE 353 NIKKISO CO., LTD.: BUSINESS OVERVIEW
  • TABLE 354 NIKKISO CO., LTD: PRODUCTS & SERVICES OFFERED
  • TABLE 355 MACOPHARMA SA: BUSINESS OVERVIEW
  • TABLE 356 MACOPHARMA SA: PRODUCTS & SERVICES OFFERED
  • TABLE 357 MILTENYI BIOTEC: BUSINESS OVERVIEW
  • TABLE 358 MILTENYI BIOTEC: PRODUCTS & SERVICES OFFERED
  • TABLE 359 OTSUKA HOLDINGS CO., LTD.: BUSINESS OVERVIEW
  • TABLE 360 OTSUKA HOLDINGS CO., LTD.: PRODUCTS & SERVICES OFFERED
  • TABLE 361 MEDICA S.P.A: BUSINESS OVERVIEW
  • TABLE 362 MEDICA S.P.A: PRODUCTS & SERVICES OFFERED
  • TABLE 363 MEDICA S.P.A: EXPANSIONS
  • TABLE 364 MALLINCKRODT PLC: BUSINESS OVERVIEW
  • TABLE 365 MALLINCKRODT PLC: PRODUCTS & SERVICES OFFERED
  • TABLE 366 MALLINCKRODT PLC: PRODUCT LAUNCHES & APPROVALS
  • TABLE 367 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
  • TABLE 368 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED
  • TABLE 369 LMB TECHNOLOGIE GMBH: BUSINESS OVERVIEW
  • TABLE 370 LMB TECHNOLOGIE GMBH: PRODUCTS & SERVICES OFFERED
  • TABLE 371 BIOELETTRONICA S.R.L.: BUSINESS OVERVIEW
  • TABLE 372 BIOELETTRONICA S.R.L: PRODUCTS & SERVICES OFFERED
  • TABLE 373 INFOMED SA: BUSINESS OVERVIEW
  • TABLE 374 INFOMED SA: PRODUCTS & SERVICES OFFERED
  • TABLE 375 CYTOSORBENTS CORPORATION: BUSINESS OVERVIEW
  • TABLE 376 CYTOSORBENTS CORPORATION: PRODUCTS & SERVICES OFFERED
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 PRIMARY SOURCES
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
  • FIGURE 5 TOP-DOWN APPROACH
  • FIGURE 6 MARKET SIZE ESTIMATION: DEMAND-SIDE ASSESSMENT
  • FIGURE 7 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029): IMPACT LEVEL
  • FIGURE 8 CAGR PROJECTIONS
  • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • FIGURE 10 APHERESIS DISPOSABLES TO BE LARGEST SEGMENT DURING FORECAST PERIOD
  • FIGURE 11 CENTRIFUGAL APHERESIS DEVICES SEGMENT TO REGISTER FASTEST GROWTH DURING FORECAST PERIOD
  • FIGURE 12 AUTOMATED BLOOD COLLECTION TO BE LEADING SEGMENT DURING FORECAST PERIOD
  • FIGURE 13 THERAPEUTIC APHERESIS DISPOSABLES TO HOLD DOMINANT SHARE BY 2029
  • FIGURE 14 NEUROLOGICAL DISORDERS TO BE LEADING SEGMENT DURING FORECAST PERIOD
  • FIGURE 15 CENTRIFUGATION TECHNOLOGY TO DOMINATE APHERESIS MARKET DURING FORECAST PERIOD
  • FIGURE 16 CONTINUOUS FLOW CENTRIFUGATION TO BE MAJOR SEGMENT DURING FORECAST PERIOD
  • FIGURE 17 PLASMAPHERESIS SEGMENT TO HOLD LARGEST SHARE BY 2029
  • FIGURE 18 COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS – MAJOR SEGMENT BY 2029
  • FIGURE 19 ASIA PACIFIC TO BE FASTEST-GROWING REGIONAL MARKET FOR APHERESIS
  • FIGURE 20 RISING PREVALENCE OF DISEASES AND GROWING NUMBER OF TRAUMA AND INJURY CASES TO DRIVE MARKET GROWTH
  • FIGURE 21 PLASMAPHERESIS AND GERMANY ACCOUNTED FOR LARGEST SHARE OF EUROPEAN APHERESIS MARKET IN 2023
  • FIGURE 22 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 23 ASIA PACIFIC MARKET TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 24 DEVELOPING MARKETS TO REGISTER FASTER GROWTH DURING FORECAST PERIOD
  • FIGURE 25 APHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 26 US: NUMBER OF PEOPLE WITH CHRONIC CONDITIONS, 1995–2030 (MILLION INDIVIDUALS)
  • FIGURE 27 EUROPE: PLASMA COLLECTION, 2012–2021 (LITERS)
  • FIGURE 28 NORTH AMERICA: PLASMA COLLECTION, 2012–2021 (LITERS)
  • FIGURE 29 FOCUS ON PERSONALIZED MEDICINE, AUTOMATION, EFFICIENCY, AND EXPANSION OF APHERESIS APPLICATIONS – LEADING TRENDS
  • FIGURE 30 APHERESIS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 31 GLOBAL NUMBER OF PATENTS PUBLICATIONS (JANUARY 2014-MARCH 2024)
  • FIGURE 32 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR APHERESIS PATENTS (JANUARY 2014- MARCH 2024)
  • FIGURE 33 TOP APPLICANT COUNTRIES/REGIONS FOR APHERESIS (JANUARY 2013- MARCH 2024)
  • FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR APHERESIS PRODUCTS
  • FIGURE 35 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS
  • FIGURE 36 APHERESIS MARKET: ECOSYSTEM
  • FIGURE 37 APHERESIS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 38 LEUKAPHERESIS PRODUCTS MARKET OVERVIEW
  • FIGURE 39 LEUKOPAKS MARKET OVERVIEW
  • FIGURE 40 INVESTMENT AND FUNDING SCENARIO: APHERESIS MARKET (2018–2023)
  • FIGURE 41 APHERESIS MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 42 NORTH AMERICA: APHERESIS MARKET SNAPSHOT
  • FIGURE 43 ASIA PACIFIC: APHERESIS MARKET SNAPSHOT
  • FIGURE 44 OVERVIEW OF STRATEGIES DEPLOYED BY APHERESIS MARKET PLAYERS
  • FIGURE 45 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2023)
  • FIGURE 46 APHERESIS MARKET SHARE ANALYSIS (2023)
  • FIGURE 47 CENTRIFUGATION: APHERESIS MARKET SHARE ANALYSIS (2023)
  • FIGURE 48 MEMBRANE SEPARATION: APHERESIS MARKET SHARE ANALYSIS (2023)
  • FIGURE 49 APHERESIS MARKET: COMPANY EVALUATION MATRIX, KEY PLAYERS, 2023
  • FIGURE 50 APHERESIS MARKET: COMPANY FOOTPRINT
  • FIGURE 51 APHERESIS MARKET: COMPANY EVALUATION MATRIX, START-UPS/SMES, 2023
  • FIGURE 52 TERUMO BCT, INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 53 FRESENIUS SE & CO KGAA: COMPANY SNAPSHOT (2022)
  • FIGURE 54 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 55 BAXTER INTERNATIONAL INC: COMPANY SNAPSHOT (2023)
  • FIGURE 56 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 57 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2022)
  • FIGURE 58 CERUS CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 59 KANEKA CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 60 SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 61 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022)
  • FIGURE 62 OTSUKA HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2022)
  • FIGURE 63 MALLINCKRODT PLC: COMPANY SNAPSHOT (2022)
  • FIGURE 64 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
  • FIGURE 65 CYTOSORBENTS CORPORATION: COMPANY SNAPSHOT (2022)

The study involved four major activities to estimate the current size of the apheresis market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for the study of apheresis Market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

Extensive primary research was conducted after obtaining information regarding the apheresis market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand and supply sides across major countries of North America, Europe, Asia Pacific,  Latin America, and the Middle East & Africa. Primary data was collected through questionnaires, emails, and telephonic interviews. The primary sources from the supply side included various industry experts, such as Chief X Officers (CXOs), Vice Presidents (VPs), Directors from business development, marketing, product development/innovation teams, and related key executives from manufacturers; distributors operating in the apheresis market.; and key opinion leaders.

Primary interviews were conducted to gather insights such as market statistics, data on revenue collected from the products and services, market breakdowns, market size estimations, market forecasting, and data triangulation. Primary research also helped in understanding the various trends related to technology, application, vertical, and region. Stakeholders from the demand side customers/end users who are using infection control products were interviewed to understand the buyer’s perspective on the suppliers, products, and their current usage and the future outlook of their business, which will affect the overall market.

The following is a breakdown of the primary respondents:

Breakdown of Primary Participants:

Apheresis Market Size, and Share

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Other primaries include sales managers, marketing managers, and product managers.
Note 3: Companies are classified into tiers based on their total revenue.
As of 2023: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, Tier 3=<USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The research methodology used to estimate the size of the apheresis market includes the following details.

The market sizing of the market was undertaken from the global side.

Country-level Analysis: The size of the apheresis market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products in the overall apheresis market was obtained from secondary data and validated by primary participants to arrive at the total apheresis market. Primary participants further validated the numbers.

Geographic market assessment (by region & country): The geographic assessment was done using the following approaches:

Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends

Approach 2: Geographic adoption trends for individual product segments by end users and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)

At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall apheresis market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.

Global Apheresis Market Size: Top-Down Approach

Apheresis Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Apheresis Market Size: Bottom-Up Approach

Apheresis Market Size, and Share

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the apheresis industry.

Market Definition:

The apheresis market encompasses the global business sphere surrounding the development, production, distribution, and use of apheresis equipment and related consumables. This specialized technology enables the separation and collection of specific blood components, such as plasma, platelets, or white blood cells, from a whole blood donation. These collected components are then used in various therapeutic applications, including treating blood disorders, autoimmune diseases, and neurological conditions.

Key Stakeholders

  • Apheresis devices manufacturers and distributors
  • Hospitals and transfusion centers
  • Therapeutic apheresis service providers
  • Blood banks and blood collection centers
  • Plasma fractionation companies
  • Healthcare providers
  • Academic research institutes
  • Pharmaceutical companies
  • Contract research organizations (CROs)
  • Market research & consulting firms

Report Objectives

  • To define, describe, segment, and forecast the global apheresis market by product, technology, procedure, application, end user, and region.
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall apheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
  • To forecast the size of the apheresis market in five main regions along with their respective key countries, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players in the global apheresis market and comprehensively analyze their core competencies2 and market shares.
  • To track and analyze competitive developments such as acquisitions, expansions, partnerships, agreements, and collaborations; and product launches and approvals.
  • To benchmark players within the apheresis market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

  • Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
  • Geographic Analysis:  Further breakdown of the Latin American apheresis into specific countries and, the Middle East, and Africa apheresis into specific countries and further breakdown of the European apheresis into specific countries

Previous Versions of this Report

Apheresis Market by Product [Device (Centrifugation, Membrane Separation) Disposable], Procedure (Donor, Therapeutic), Application (Plasmapheresis, Plateletpheresis), Technology, End User (Hospital, Blood Collection Center) & Region - Global Forecasts to 2025

Report Code MD 1407
Published in Apr, 2024, By MarketsandMarkets™

Apheresis Market by Product [Device (Centrifugation, Membrane Separation) Disposable], Procedure (Donor, Therapeutic), Application (Plasmapheresis, Plateletpheresis), Technology, End-User (Hospital, Blood Collection Center), Region - Global Forecast to 2025

Report Code MD 1407
Published in Feb, 2020, By MarketsandMarkets™

Apheresis Market by Product (Plasma & Component Separator, Hemoperfusion, Disposable), Procedure (Therapeutic, Photopheresis, Donor), Application (Plasmapheresis, Plateletpheresis), Technology (Centrifuge, Membrane Separation) - Global Forecast to 2021

Report Code MD 1407
Published in Feb, 2017, By MarketsandMarkets™

Apheresis Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, Donor Apheresis/Apheresis Blood Donation), by Technology and by Product - Global Forecast to 2020

Report Code MD 1407
Published in Sep, 2015, By MarketsandMarkets™

Apheresis Market - (Therapeutic & Donor Apheresis/Automated Blood Component Collection), Applications (Plasmapheresis, Plateletpheresis, RBC/Erythrocytapheresis, Leukapheresis, Photopheresis), Devices & Disposables - Forecasts To 2017

Report Code MD 1407
Published in Jan, 2013, By MarketsandMarkets™

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Apheresis Market

DMCA.com Protection Status